HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up.

Abstract
To evaluate the long-term impact of the reduction of Philadelphia chromosome (Ph)-positive metaphases by treatment of chronic myelogenous leukaemia (CML) with interferon (IFN) alpha, we examined the outcome of 62 patients who had been enrolled between 1984 and 1990 into 2 IFN trials at our institution. As best cytogenetic response, 9 patients had achieved a complete remission and an additional 9 patients a partial remission. The remaining 44 patients had obtained either a minimal (n=29) or no cytogenetic response (n=15). Of the total of 62 patients, 9 were still on schedule and responsive to IFN in January 1995, including 7 patients in ongoing complete cytogenetic remission. The overall 5-year survival rate after a median follow-up from diagnosis of 51 months (range 3-102 months) was 62% and the median survival was reached at month 87. The effect of cytogenetic remission on survival was examined by "landmark" studies showing a significant survival advantage for patients with karyotype responses. In conclusion, in the patients studied, cytogenetic improvement was found to translate into improved survival expectancy. Long-term control by IFN alpha of CML, however, was restricted to a small minority of patients, predominantly to those attaining a complete suppression of the leukaemic cell clone as judged by cytogenetic criteria.
AuthorsO Kloke, N Niederle, B Opalka, I Hawig, S Seeber, R Becher
JournalEuropean journal of haematology (Eur J Haematol) 1996 Jan-Feb Vol. 56 Issue 1-2 Pg. 78-81 ISSN: 0902-4441 [Print] England
PMID8599999 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
Topics
  • Actuarial Analysis
  • Adolescent
  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Genetic Techniques
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (therapeutic use)
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (genetics, mortality, pathology, therapy)
  • Male
  • Metaphase
  • Middle Aged
  • Philadelphia Chromosome
  • Predictive Value of Tests
  • Prognosis
  • Recombinant Proteins
  • Remission Induction
  • Survival Rate
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: